

Asymmetric Synthesis of Substituted NH-Piperidines from Chiral Amines

Lekh Nath Gautam,^a Yijin Su,^a Novruz G. Akhmedov,^a Jeffrey L. Petersen,^a and Xiaodong Shi*^a

^aC. Eugene Bennett Department of Chemistry, West Virginia University, Morgantown, WV
26506, United States

Email: xiaodong.shi@mail.wvu.edu

Supplementary Information

Table of Contents

Pages

I. Experimental Section	S2---S7
I. ¹ H NMR and ¹³ C NMR Spectra	S8---S41
II. HPLC Profiles	S42---S52
III. OTEP crystal structure of 3b minor	S---53

General Information. All of the reactions dealing with air and/or moisture-sensitive reactions were carried out under an atmosphere of nitrogen using oven/flame-dried glassware and standard syringe/septa techniques. Unless otherwise noted, all commercial reagents were obtained from the commercial provider and used without further purification. ¹H-NMR and ¹³C-NMR spectra were recorded on 600 MHz spectrometers. Chemical shifts were reported relative to internal tetramethylsilane (δ 0.00 ppm) or CDCl₃ (δ 7.26 ppm) for ¹H and CDCl₃ (δ 77.0 ppm) for ¹³C. Flash column chromatography was performed on 230-430 mesh silica gel. Analytical thin layer chromatography was performed with precoated glass baked plates (250 μ) and visualized by fluorescence and by charring after treatment with potassium permanganate stain. R_f-values were obtained by elution in the stated solvent ratios. Optical rotations were measured on a commercial automatic polarimeter and reported as follows: $[\alpha]_D^{25}$ (c = mg/mL, solvent). HRMS were recorded on LTQ-FTUHRA spectrometer (ESI-MS). All the solvents were distilled freshly according to standard procedures. High-performance Liquid chromatography (HPLC) was performed using a Daicel Chiralcel OD-H column (250*4.6 mm) or Chiralpak AS-H (250*4.6 mm). Enantiomeric excess was determined by HPLC analysis, described below in detail.

General Procedure for the Preparation of Substituted *N*-protected Piperidine (3d-3j). To a solution of nitroalkene **1a** (149 mg, 1 mmol, 1 eq.) in dry THF (2 mL, 0.5 M), were added successively Chiral 4-methoxyphenylethanamine (227 mg, 1.5 mmol, 1.5 eq.) and MVK (140 mg, 2.0 mmol, 2.0 eq.) under N₂ atmosphere. The mixture was stirred at room temperature for 36 hr and monitored by TLC. After removing the solvent, the residue was purified by flash silica gel chromatography (Hexane-EtOAc v/v 8:1), which gave a major diastereomeric **piperidine 3d** (266 mg, 0.72 mmol, yield: 72%) as white solid.

(2S,3S,4R)-1-((S)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitro-2-phenylpiperidin-4-ol (3d major) was purified by flash silica gel chromatography (Hexane- EtOAc, v/v 8/1) as white solid, 266 mg, yield 72%. ¹H NMR (600 MHz, CDCl₃): δ 7.19-7.40 (m, 7H), 6.76 (d, *J* = 8.2 Hz, 2H), 4.64 (d, *J* = 10.1 Hz, 1H), 4.27 (d, *J* = 10.1 Hz, 1H), 3.72 (s, 3H), 3.66 (q, *J* = 6.2 Hz, 1H), 2.96 (s, 1H), 2.77 (t, *J* = 11.7 Hz, 1H), 2.30 (d, *J* = 13.6 Hz, 1H), 1.71 (d, *J* = 13.9 Hz, 1H), 1.51 (t, *J* = 13.2 Hz, 1H), 1.22 (s, 3H), 1.15 (d, *J* = 6.7 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃): δ 158.5, 137.2, 135.5, 129.2, 129.1, 129.0, 128.6, 113.5, 98.5, 69.5, 63.9, 55.4, 54.5, 38.7, 37.1, 27.5, 8.9. HRMS Calculated for C₂₁H₂₇N₂O₄ [M+H]⁺: 371.19453, Found: 371.19475.

(2S,3S,4R)-2-(4-chlorophenyl)-1-((S)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitropiperidin-4-ol (3e major) was purified by flash silica gel chromatography (Hexane- EtOAc, v/v 8/1) as white solid, 303 mg, yield 75%. ¹H NMR (600 MHz, CDCl₃): δ 7.43-7.33 (m, 4H), 7.22 (d, *J* = 8.6 Hz, 2H), 6.82 (d, *J* = 8.8 Hz, 2H), 4.64 (d, *J* = 10.1 Hz, 1H), 4.32 (d, *J* = 10.1 Hz, 1H), 3.78 (s, 3H), 3.66 (q, *J* = 6.9 Hz, 1H), 2.94 (s, 1H), 2.81 (td, *J* = 12.2, 2.5 Hz,

1H), 2.36 (td, $J = 11.9, 4.2$ Hz, 1H), 1.76 (td, $J = 13.8, 2.5$ Hz, 1H), 1.57 (d, $J = 6.7$ Hz, 1H), 1.22 (s, 3H), 1.20 (d, $J = 6.9$ Hz, 3H). ^{13}C NMR (150 MHz, CDCl_3): δ 158.5, 136.7, 135.8, 135.1, 134.7, 129.5, 128.6, 127.5, 113.5, 98.3, 69.5, 63.2, 55.4, 54.7, 38.7, 37.1, 27.5, 8.9. HRMS Calculated for $\text{C}_{21}\text{H}_{26}\text{ClN}_2\text{O}_4$ $[\text{M}+\text{H}]^+$: 405.15029, Found: 405.15120.

(2*S*,3*S*,4*R*)-2-(4-fluorophenyl)-1-((*S*)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitropiperidin-4-ol (3*f* major) was purified by flash silica gel chromatography (Hexane- EtOAc, v/v 9/1) as white solid, 283 mg, yield 73%. ^1H NMR (600 MHz, CDCl_3): δ 7.46-7.38 (m, 2H), 7.25-7.23 (m, 2H), 7.05 (d, $J = 7.9$ Hz, 2H), 6.82 (d, $J = 8.6$ Hz, 2H), 4.64 (d, $J = 7.8$ Hz, 1H), 4.33 (d, $J = 10.1$ Hz, 1H), 3.78 (s, 3H), 3.67 (d, $J = 6.6$ Hz, 3H), 2.97 (s, 1H), 2.81 (t, $J = 11.1$ Hz, 1H), 2.36 (d, $J = 7.2$ Hz, 1H), 1.76 (d, $J = 15.4$ Hz, 1H), 1.50 (m, 1H), 1.27 (s, 3H), 1.20 (d, $J = 6.4$ Hz, 3H). ^{13}C NMR (150 MHz, CDCl_3): δ 163.0, 158.3, 136.5, 135.6, 134.9, 134.5, 129.3, 129.2, 128.3, 113.3, 98.1, 69.2, 63.0, 55.2, 54.4, 38.4, 36.8, 27.2, 8.7. HRMS Calculated for $\text{C}_{21}\text{H}_{26}\text{FN}_2\text{O}_4$ $[\text{M}+\text{H}]^+$: 389.18319, Found: 389.18301.

(2*S*,3*S*,4*R*)-2-(4-methoxyphenyl)-1-((*S*)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitropiperidin-4-ol (3*g* major) was purified by flash silica gel chromatography (Hexane- EtOAc, v/v 8/1) as white solid, 220 mg, yield 55%. ^1H NMR (600 MHz, CDCl_3): δ 7.40-7.35 (m, 4H), 6.88 (d, $J = 8.1$ Hz, 2H), 6.81 (d, $J = 8.6$ Hz, 2H), 4.67 (d, $J = 10.0$ Hz, 1H), 4.28 (d, $J = 10.1$ Hz, 1H), 3.78 (s, 3H), 3.77 (s, 3H), 3.73 (d, $J = 6.9$ Hz, 1H), 3.02 (s, 1H), 2.80 (t, $J = 10.1$ Hz, 1H), 2.35 (d, $J = 15.4$ Hz, 1H), 1.76 (d, $J = 13.8$ Hz, 1H), 1.56 (d, $J = 11.3$ Hz, 1H), 1.27 (s, 3H), 1.20 (d, $J = 6.7$ Hz, 3H). ^{13}C NMR (150 MHz, CDCl_3): δ 159.9, 158.4, 135.6, 128.9, 128.6, 114.6, 113.5, 98.6, 69.5, 63.3, 55.4, 38.8, 37.1, 27.5, 8.90. HRMS Calculated for $\text{C}_{22}\text{H}_{29}\text{N}_2\text{O}_5$ $[\text{M}+\text{H}]^+$: 401.20318, Found: 401.20322.

(2*S*,3*S*,4*R*)-1-((*S*)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitro-2-(*p*-tolyl)piperidin-4-ol (3*h* major) was purified by flash silica gel chromatography (Hexane- EtOAc, v/v 9/1) as white solid, 253 mg, yield 66%. ^1H NMR (600 MHz, CDCl_3): δ 7.39-7.24 (m, 4H), 7.16 (d, $J = 7.9$ Hz, 2H), 6.83 (d, $J = 8.6$ Hz, 2H), 4.71 (d, $J = 10.1$ Hz, 1H), 4.31 (d, $J = 10.0$ Hz, 1H), 3.79 (s, 3H), 3.74 (q, $J = 6.7$ Hz, 3H), 3.05 (s, 1H), 2.82 (td, $J = 12.3, 2.3$ Hz, 1H), 2.36 (d, $J = 4.4$ Hz, 1H), 2.32 (s, 3H), 1.76 (d, $J = 13.8$ Hz, 1H), 1.57 (td, $J = 12.9, 3.8$ Hz, 1H), 1.28 (s, 3H), 1.21 (d, $J = 6.7$ Hz, 3H). ^{13}C NMR (150 MHz, CDCl_3): δ 158.4, 138.7, 135.6, 134.0, 129.9, 128.6, 126.0, 113.5, 98.5, 69.5, 63.7, 55.4, 54.4, 38.7, 37.2, 27.5, 21.4, 8.9. HRMS Calculated for $\text{C}_{22}\text{H}_{29}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$: 385.20826, Found: 385.20491.

(2*R*,3*S*,4*R*)-2-(furan-2-yl)-1-((*S*)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitropiperidin-4-ol (3*i*) was purified by flash silica gel chromatography (Hexane- EtOAc, v/v 9/1) as white solid, 263 mg, yield: 73%. ^1H NMR (150 MHz, CDCl_3): δ 7.34-7.33 (m, 3H), 7.05 (m, 1H), 6.91 (m, 1H), 6.84 (d, $J = 8.4$ Hz, 1H), 4.71 (d, $J = 10.1$ Hz, 1H), 4.34 (d, $J = 10.1$ Hz, 1H), 3.78 (s, 3H), 3.72 (m, 1H), 3.64 (s, 1H), 2.82 (t, $J = 10.0$ Hz, 1H), 2.35 (d, $J = 14.2$ Hz, 1H), 1.76 (d, $J = 13.8$ Hz, 1H), 1.59 (m, 1H), 1.27 (s, 3H), 1.21 (d, $J = 6.9$ Hz, 3H). ^{13}C NMR (150 MHz, CDCl_3): δ 158.2, 136.9, 135.3, 129.0, 129.1, 128.4, 125.9, 132.0, 98.3, 69.2, 63.7, 55.2, 54.3, 38.5, 36.9, 27.3, 8.6. HRMS Calculated for $\text{C}_{19}\text{H}_{25}\text{N}_2\text{O}_5$ $[\text{M}+\text{H}]^+$: 361.17188, Found: 361.17156.

(2*R*,3*S*,4*R*)-1-((*S*)-1-(4-methoxyphenyl)ethyl)-4-methyl-3-nitro-2-(thiophen-2-yl)piperidin-4-ol (3*j* major) was purified by flash silica gel chromatography (Hexane- EtOAc, v/v 9/1) as white solid, 271 mg, yield 72%. ^1H

NMR (600 MHz, CDCl₃): δ 7.33-7.31 (m, 4H), 7.04 (m, 1H), 6.90 (t, J = 4.4 Hz, 1H), 6.83 (d, J = 8.6 Hz, 1H), 4.70 (m, 2H), 3.78 (s, 3H), 2.97 (m, 1H), 2.83 (td, J = 12.4, 2.5 Hz, 1H), 2.32 (d, J = 10.5 Hz, 1H), 1.75 (d, J = 13.76 Hz, 1H), 1.56 (m, 1H), 1.27 (s, 3H), 1.25 (d, J = 6.7 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃): δ 158.4, 137.2, 135.5, 129.2, 129.1, 129.0, 128.6, 113.5, 98.5, 69.5, 63.9, 55.4, 54.5, 38.7, 37.1, 27.5, 8.9. HRMS Calculated for C₁₉H₂₅N₂O₄S [M+H]⁺: 377.1535, Found: 377.1534.

General Procedure for the Preparation of *NH*-piperidine (4a-4g). TFA was added dropwise to a stirred solution of the substrate **3d** (266 mg, 0.72 mmol) in minimum amount of DCM and stirred at room temperature 12-18hr (TFA:DCM = 1:1). After concentration in rotary evaporator, the residue was partitioned between saturated aqueous sodium bicarbonate solution (8ml) and Dichloromethane (8ml). The separated aqueous phase was extracted with Dichloromethane (3×8ml), and the combined organic extracts dried over sodium or magnesium sulfate for 2hr then filtered through the cotton plug. Finally, the dilute solution was concentrated in vacuo and the residue was purified by column chromatography using solvent system (Dichloromethane: Methanol from 200:1 to 50:1) to afford piperidine **4a**. Using the same mentioned procedure other *NH*-piperidines were prepared from **3d-3j**.

(2*S*,3*S*,4*R*)-4-methyl-3-nitro-2-phenylpiperidin-4-ol (-4a) and (2*R*,3*R*,4*S*)-4-methyl-3-nitro-2-phenylpiperidin-4-ol (+4a) was purified by flash silica gel chromatography (CH₂Cl₂-MeOH, v/v 100/1) as solid, -**4a**, 149 mg, yield 88%; +**4a**, 151 mg, yield 89%. ¹H NMR (600 MHz, CDCl₃): δ 7.37-7.28 (m, 5H), 4.56 (d, J = 10.3 Hz, 1H), 4.45 (d, J = 10.3 Hz, 1H), 3.29 (td, J = 12.3, 2.9 Hz, 1H), 2.92 (ddd, J = 12.1, 4.8, 2.2 Hz, 1H), 1.89 (dt, J = 13.8, 2.5 Hz, 1H), 1.71 (td, J = 12.6, 4.8 Hz, 1H), 1.31 (s, 3H). ¹³C NMR (150 MHz, CDCl₃): δ 138.2, 129.1, 129.0, 127.7, 96.9, 69.9, 60.4, 41.5, 38.1, 27.7. HRMS Calculated for C₁₂H₁₇N₂O₃ [M+H]⁺: 237.11945, Found: 237.11933. Enantiomeric excess of the piperidine was determined by HPLC analysis with a Chiralcel OD-H column (90:10 hexane: isopropanol, 0.9 mL/min, 220 nm); Racemic mixture t_{R1} = 13.8 min, t_{R2} = 17.8 min; Enantiopure isomer: -**4a**: >95% ee, t_R = 19.2 min; +**4a**: >95% ee, t_R = 14.1 min; and optical rotation [α]_D²⁰ -25.6 and + 25.6 (c = 0.1, CH₂Cl₂).

(2*S*,3*S*,4*R*)-2-(4-chlorophenyl)-4-methyl-3-nitropiperidin-4-ol (-4b) was purified by flash silica gel chromatography (CH₂Cl₂-MeOH, v/v 100/1) as solid, 186 mg, yield 92%. ¹H NMR (600 MHz, CDCl₃): δ 7.32-7.24 (m, 4H), 4.47 (d, J = 10.2 Hz, 1H), 4.43 (d, J = 10.2 Hz, 1H), 3.28 (td, J = 12.5, 2.7 Hz, 1H), 2.90 (dd, J = 11.7, 4.7 Hz, 1H), 1.86 (dt, J = 13.7, 2.7 Hz, 1H), 1.68 (td, J = 12.5, 5.1 Hz, 1H), 1.31 (s, 3H). ¹³C NMR (150 MHz, CDCl₃): δ 136.7, 134.6, 129.0, 128.9, 96.7, 69.7, 59.6, 41.3, 37.8, 27.4. HRMS Calculated for C₁₂H₁₆ClN₂O₃ [M+H]⁺: 272.07417, Found: 272.07327. Enantiomeric excess of the piperidine was determined by HPLC analysis with a Chiralcel OD-H column (90:10 hexane: isopropanol, 0.9 mL/min, 220 nm); Racemic mixture: t_{R1} = 16.5 min, t_{R2} = 19.1 min; Enantiopure isomer: >95% ee, t_R = 16.4 min and [α]_D²⁰ -34.4 (c = 0.1, CH₂Cl₂).

(2*S*,3*S*,4*R*)-2-(4-fluorophenyl)-4-methyl-3-nitropiperidin-4-ol (-4c) was purified by flash silica gel chromatography (CH₂Cl₂-MeOH, v/v 100/1) as solid, 167 mg, yield 90%. ¹H NMR (600 MHz, CDCl₃): δ 7.33 (t, J

= 6.7 Hz, 2H), 6.99 (d, J = 6.7 Hz, 2H), 4.48 (d, J = 10.2 Hz, 1H), 4.43 (d, J = 10.2 Hz, 1H), 3.28 (td, J = 12.1, J = 2.7 Hz, 1H), 2.90 (dq, J = 11.7, 2.0 Hz, 1H), 1.87 (dt, J = 13.7, 2.4 Hz, 1H), 1.69 (td, J = 13.7, 4.7 Hz, 1H), 1.31 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3): δ 164.3, 161.9, 134.3, 129.5, 129.4, 116.1, 115.9, 97.2, 70.0, 59.8, 41.6, 38.1, 27.7 HRMS Calculated for $\text{C}_{12}\text{H}_{16}\text{FN}_2\text{O}_3$ $[\text{M}+\text{H}]^+$: 255.1103, Found: 255.1133. Enantiomeric excess of the piperidine was determined by HPLC analysis with a Chiralcel OD-H column (90:10 hexane: isopropanol, 0.9 mL/min, 220 nm); Racemic mixture: $t_{\text{R}1}$ = 16.6 min, $t_{\text{R}2}$ = 21.4 min; Enantiopure isomer: >95% ee, t_{R} = 16.2 min and $[\alpha]_{\text{D}}^{20}$ -39.5 (c = 0.1, CH_2Cl_2).

(2*S*,3*S*,4*R*)-4-methyl-3-nitro-2-(*p*-tolyl)piperidin-4-ol (-4*d*) was purified by flash silica gel chromatography (CH_2Cl_2 -MeOH, v/v 100/1) as solid, 127 mg, yield 77%. ^1H NMR (600 MHz, CDCl_3): δ 7.23 (d, J = 8.2 Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H), 4.52 (d, J = 10.2 Hz, 1H), 4.41 (d, J = 10.2 Hz, 1H), 3.28 (td, J = 12.5, 2.7 Hz, 1H), 2.91 (dd, J = 11.7, 2.3 Hz, 1H), 2.30 (s, 3H), 1.88 (d, J = 11.7 Hz, 1H), 1.66 (td, J = 13.3, 4.7 Hz, 1H), 1.31 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3): δ 138.6, 135.0, 129.4, 127.3, 96.8, 69.7, 60.0, 41.3, 37.9, 27.4, 21.1; HRMS Calculated for $\text{C}_{13}\text{H}_{19}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$: 251.13510, Found: 251.13521. Enantiomeric excess of the piperidine was determined by HPLC analysis with a Chiralcel OD-H column (90:10 hexane: isopropanol, 0.9 mL/min, 220 nm); Racemic mixture: $t_{\text{R}1}$ = 15.9 min, $t_{\text{R}2}$ = 18.4 min; Enantiopure isomer: >95% ee, t_{R} = 16.4 min and $[\alpha]_{\text{D}}^{20}$ -29.3 (c = 0.1, CH_2Cl_2).

(2*S*,3*S*,4*R*)-2-(4-methoxyphenyl)-4-methyl-3-nitropiperidin-4-ol (-4*e*) was purified by flash silica gel chromatography (CH_2Cl_2 -MeOH, v/v 100/1) as solid, 109 mg, yield 75%. ^1H NMR (600 MHz, CDCl_3): δ 7.27 (d, J = 9.0 Hz, 2H), 6.82 (d, J = 9.0 Hz, 2H), 4.51 (d, J = 10.2 Hz, 1H), 4.39 (d, J = 10.2 Hz, 1H), 3.76 (s, 3H), 2.82 (td, J = 12.1, 2.7 Hz, 1H), 2.90 (dd, J = 11.7, 2.0 Hz, 1H), 1.86 (dt, J = 13.7 Hz, 1H), 1.68 (m, 1H), 1.31 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3): δ 159.8, 130.1, 128.6, 114.1, 96.9, 69.7, 59.7, 55.2, 41.4, 37.8, 27.4 HRMS Calculated for $\text{C}_{13}\text{H}_{18}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$: 267.13001, Found: 267.13054. Enantiomeric excess of the piperidine was determined by HPLC analysis with a Chiralcel OD-H column (95:5 hexane: isopropanol, 0.5 mL/min, 220 nm); Racemic mixture: $t_{\text{R}1}$ = 27.1 min, $t_{\text{R}2}$ = 34.4 min; Enantiopure isomer: >95% ee, t_{R} = 35.5 min and $[\alpha]_{\text{D}}^{20}$ -42.7 (c = 0.1, CH_2Cl_2).

(2*R*,3*S*,4*R*)-2-(furan-2-yl)-4-methyl-3-nitropiperidin-4-ol (-4*f*) was purified by flash silica gel chromatography (CH_2Cl_2 -MeOH, v/v 100/1) as solid, 108 mg, yield 65%. ^1H NMR (600 MHz, CDCl_3): δ 7.35 (m, 1H), 6.27 (m, 2H), 4.67 (d, J = 10.2 Hz, 1H), 4.62 (d, J = 10.2 Hz, 1H), 3.33 (s, 1H), 3.26 (td, J = 12.5, 2.7 Hz, 1H), 2.93 (dd, J = 12.5, 2.0 Hz, 1H), 1.88 (d, J = 14.1 Hz, 1H), 1.33 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3): δ 143.2, 110.5, 108.6, 94.6, 69.8, 53.8, 41.1, 38.5, 29.9, 27.7 HRMS Calculated for $\text{C}_{10}\text{H}_{15}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$: 227.09871, Found: 227.09751. Enantiomeric excess of the piperidine was determined by HPLC analysis with a Chiralcel OD-H column (90:10 hexane: isopropanol, 1 mL/min, 220 nm); Racemic mixture: $t_{\text{R}1}$ = 19.1 min, $t_{\text{R}2}$ = 25.1 min; Enantiopure isomer: >95% ee, t_{R} = 18.4 min and $[\alpha]_{\text{D}}^{20}$ +57.2 (c = 0.1, CH_2Cl_2).

(2*R*,3*S*,4*R*)-4-methyl-3-nitro-2-(thiophen-2-yl)piperidin-4-ol (-4*g*) was purified by flash silica gel chromatography (CH_2Cl_2 -MeOH, v/v 100/1) as solid, 148 mg, yield: 85%. ^1H NMR (600 MHz, CDCl_3): δ 7.24 (d, J = 4.7 Hz, 1H), 6.94 (d, J = 3.5 Hz, 2H), 6.90 (t, J = 5.1 Hz, 1H), 4.81 (d, J = 10.2 Hz, 1H), 4.47 (d, J = 10.2 Hz, 1H), 3.28 (td, J = 12.1, 2.2 Hz, 1H), 2.90 (dq, J = 11.7, 2.3 Hz, 1H), 1.87 (dt, J = 13.7, 2.7 Hz, 1H), 1.69 (td, J = 12.5, 5.1 Hz, 1H), 1.30 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3): δ 141.9, 126.9, 126.2, 125.9, 98.1, 70.0, 56.1, 36.4, 28.4, 26.9; HRMS Calculated for $\text{C}_{10}\text{H}_{15}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$: 243.07587, Found: 243.07551. Enantiomeric excess of the

piperidine was determined by HPLC analysis with a Chiralcel OD-H column (90:10 hexane: isopropanol, 1 mL/min, 220 nm); Racemic mixture: $t_{R1} = 20.1$ min, $t_{R2} = 26.7$ min; Enantiopure isomer: >95% ee, $t_R = 26.3$ min and $[\alpha]_D^{20} +51.8$ ($c = 0.1$, CH_2Cl_2).

General Procedure for the Preparation of Thiourea-Based-Piperidine (5 and 6). To a solution of 3d (major) (800 mg, 2.16 mmol, 1eq) were added 1N HCl in MeOH (25 mL, >10 eq.) and Zn powder (2.20 g, 34.6 mmol, 15 eq.). The mixture was then stirred at room temperature and monitored by TLC. After the complete consumption of 3d, MeOH was completely evaporated followed by treatment with saturated aqueous NaHCO_3 until $\text{pH} > 10$, and CH_2Cl_2 . Organic layer was extracted with CH_2Cl_2 (30 mL x 5). The combined organic layer was washed with brine and then dried over anhydrous Na_2SO_4 . After filtration and evaporation, the residue was dissolved in minimum CH_2Cl_2 and purified by flash silica gel chromatography (CH_2Cl_2 -MeOH v/v 100:1), which gave almost quantitative amount of **5** (700 mg, 2.0 mmol, yield 95%).

To a solution of amine **5** (700 mg, 2.0mmol) in 20 ml dichloromethane was added 3,5 di-trifluoromethyl-phenyl isothiocyanate (557 mg, 2.0 mmol, 1.0 eq.) and stirred for overnight. After, TLC showed the disappearance of **5**, the solution was evaporated and the residue was chromatographed in solvent system (EtoAc: Hexane, v/v 5:1 to 1:1) to afford white solid **6** (1.078 g, 1.78 mmol, yield: 86%).



1-(3,5-bis(trifluoromethyl)phenyl)-3-((2S,3S,4R)-4-hydroxy-1-((S)-1-(4-methoxyphenyl)ethyl)-4-methyl-2-phenylpiperidin-3-yl)thiourea (6) was purified by flash silica gel chromatography (Hexane/EtOAc, v/v 5/1 to 1/1) as solid, 1.078g, yield 86 %. ^1H NMR (600 MHz, CDCl_3): δ 8.09 (s, 2H), 7.73 (t, $J = 10.0$ Hz, 1H), 7.65 (s, 1H), 7.49 (m, 2H) 7.31 (d, $J = 8.8$ Hz, 2H), 7.25 (t, $J = 7.2$ Hz, 1H), 7.16 (t, $J = 7.2$ Hz, 1H), 6.87 (d, $J = 8.4$ Hz, 2H), 4.93 (s, 1H), 4.73 (s, 2H), 4.65 (t, $J = 10.0$ Hz, 1H), 3.73 (s, 3H), 3.70 (m, 1H), 3.60 (q, $J = 6.85$ Hz, 1H), 2.66 (m, 2H), 2.19 (m, 1H), 1.62 (m, 1H), 1.14 (s, 3H), 1.13 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3): δ 185.7, 162.8, 147.2, 145.2, 140.8, 135.7, 135.3, 135.0, 134.7, 133.4, 132.1, 129.7, 127.0, 126.3, 120.8, 118.4, 74.9, 70.3, 68.1, 60.1, 58.9, 43.4, 43.0, 32.9, 13.3. HRMS Calculated for $\text{C}_{30}\text{H}_{32}\text{F}_6\text{N}_3\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 612.20747, Found: 612.20711.



Asymmetric Michael addition of Nitromethane to Chalcone with Chiral Organocatalysis.¹ To a solution of chalcone (1 mmol, 1.0 equiv) and nitromethane (915 mg/0.80 ml, 15 mmol, 15.0 equiv) was added thiourea-catalyst **6** (122 mg, 0.2 mmol, 20 mol%). The reaction mixture was stirred in capped vial for 6 h at 50 °C. Then the volatiles were removed by concentration and the residue purified by silica gel flash column chromatography (ethyl acetate-petroleum ether 1:15 V/V) to afford the product as white solid (253 mg, 80% yield). Enantiomeric excess was determined by HPLC on Chiralpak AS-H column (n-hexane-isopropanol 90:10 V/V, flow rate 1.0 mL/min, 220 nm), major enantiomer $t_R = 10.3$ min, minor enantiomer $t_R = 13.6$ min, 88 % ee (R) $[\alpha]_D^{25} = +$



¹ For the preparation of racemic product, see: N. Ono, A. Kamimura, H. Miyake, L. Hamamoto, and A. Kaji, *J. Org. Chem.* **1985**, *50*, 3692.



26.78 (c = 0.1, CH₂Cl₂, 88 % ee). ¹H NMR (400 MHz, CDCl₃): δ = 7.91–7.89 (m, 2H), 7.57–7.54 (m, 1 H), 7.46–7.42 (m, 2H), 7.32–7.27 (m, 5H), 4.81 (dd, *J* = 12.5, 6.6 Hz, 1H), 4.68 (dd, *J* = 12.5, 8.0 Hz, 1H), 4.22 (ps quint, *J* = 7.1 Hz, 1H), 3.50–3.37 (m, 2 H). ¹³C NMR (100 MHz, CDCl₃): δ = 196.8, 139.1, 136.3, 133.5, 129.3, 129.1, 129.0, 128.7, 127.4, 79.5, 41.5, 39.2.



III. ^1H NMR and ^{13}C NMR Spectra

























































(-) and (+) 4a











(-) and (+) 4a













































(+) **4g**



















IV HPLC profiles: Racemates and Enantiopure product



























HPLC of Asymmetric product





III. OTEP crystal structure of **3b** minor



END